Neurofibromatosis Type 1 Market Report 2026

Neurofibromatosis Type 1 Market Overview

• Neurofibromatosis Type 1 market size has reached to $8.83 billion in 2025 • Expected to grow to $13.78 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Spontaneous (De Novo) Mutation Driving The Growth Of The Market • Market Trend: Introducing Kinase Inhibitors In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neurofibromatosis Type 1 Market?

Neurofibromatosis type 1 (NF1) is a genetic disorder that primarily affects the nervous system, causing the growth of benign tumors along nerves in the skin, brain, and other parts of the body. It is caused by mutations in the NF1 gene, leading to neurofibromin deficiency, a protein that helps regulate cell growth. This results in various symptoms, including café-au-lait spots (light brown skin patches), freckling in unusual areas, learning disabilities, skeletal abnormalities, and, in some cases, vision or nerve-related complications. The main types of treatments in the neurofibromatosis type 1 (NF1) are medication, surgery, radiation therapy, and other treatments. Medication for NF1 includes pharmaceutical treatments such as MEK inhibitors, pain relievers, and antihypertensive drugs, which help reduce tumor growth, control pain, and manage complications. The disease types include plexiform neurofibromas, cutaneous neurofibromas, optic gliomas, and other related conditions. These are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are used by various end users, such as hospitals, specialty clinics, ambulatory surgical centers, and other healthcare facilities.

What Is The Neurofibromatosis Type 1 Market Growth Forecast?

The neurofibromatosis type 1 market size is expected to see strong growth in the next few years. It will grow to $13.78 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growing demand for targeted nf1 therapies, rising investment in precision oncology, expansion of optic glioma treatment options, increasing availability of advanced imaging tools, development of novel gene-based treatments. Major trends in the forecast period include increasing use of targeted therapy for tumor reduction, growing demand for early nf1 genetic testing, expansion of surgical interventions for tumor removal, rising adoption of radiation therapy for optic gliomas, increasing focus on supportive care and counseling services.

Global Neurofibromatosis Type 1 Market Segmentation

1) By Treatment: Medication, Surgery, Radiation Therapy, Other Treatments 2) By Disease Type: Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Gliomas, Other Diseases 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Medication: Targeted Therapy, Pain Management Medications, Anticonvulsants 2) By Surgery: Tumor Removal Surgery, Nerve Decompression Surgery 3) By Radiation Therapy: Stereotactic Radiosurgery, External Beam Radiation Therapy 4) By Other Treatments: Physical Therapy, Genetic Counseling, Psychological Support And Counseling

What Is The Driver Of The Neurofibromatosis Type 1 Market?

The spontaneous (de novo) mutation is expected to propel the growth of the neurofibromatosis type 1 (NF1) market going forward. Spontaneous (de novo) mutation refers to a genetic alteration that arises for the first time in an individual due to errors in DNA replication or environmental factors, rather than being inherited from parents. Rising spontaneous (de novo) mutation is attributed to increased parental age, environmental factors such as radiation and chemical exposure, and errors in DNA replication during cell division. Neurofibromatosis type 1 (NF1) contributes to spontaneous (de novo) mutations due to its high mutation rate in the NF1 gene, which frequently undergoes large deletions, insertions, or point mutations during gametogenesis, leading to new cases without a family history. For instance, in August 2023, according to the report published by Molecular Biology and Evolution, a US-based peer-reviewed journal, a total of 1.17 million autosomal and pseudoautosomal variants, averaging 11,007 variants per offspring, passed the Mendelian violation filter. Among these, 534 putative de novo mutations (DNMs) were identified in POR and TVA families, excluding those shared among siblings. Therefore, the spontaneous (de novo) mutation is driving the growth of the neurofibromatosis type 1 (NF1) market.

Key Players In The Global Neurofibromatosis Type 1 Market

Major companies operating in the neurofibromatosis type 1 market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, BeiGene Ltd, BioMarin Pharmaceutical Inc, Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc, CureAge Therapeutics, Fosun Pharmaceutical Group Co Ltd, AstraZeneca Plc, Genentech Inc, Regeneron Pharmaceuticals Inc, Amgen Inc, AbbVie Inc, GL Pharm Tech Corporation, ReCode Therapeutics Inc.

Global Neurofibromatosis Type 1 Market Trends and Insights

Major companies operating in the neurofibromatosis type 1 (NF1) market are focusing on introducing innovative products such as kinase inhibitor to improve targeted treatment and patient outcomes. A kinase inhibitor refers to a type of drug that blocks the activity of kinases, which are enzymes responsible for transferring phosphate groups to proteins, thereby regulating various cellular processes. For instance, in May 2023, AstraZeneca plc, a UK-based pharmaceutical industry company, received approval from China for Koselugo (selumetinib), treating symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged three years and above who have neurofibromatosis type 1 (NF1). This approval expands the availability of targeted treatment options for pediatric NF1 patients, enhancing disease management and improving quality of life. The introduction of Koselugo (selumetinib) in China aligns with the growing focus on precision medicine, offering a non-surgical alternative for managing inoperable plexiform neurofibromas.

What Are Latest Mergers And Acquisitions In The Neurofibromatosis Type 1 Market?

In July 2025, Merck KGaA, a Germany-based science and technology company, acquired SpringWorks Therapeutics for $3.4 billion. With this acquisition, Merck KGaA aims to expand its rare tumor portfolio and strengthen its global oncology strategy by integrating SpringWorks’ FDA-approved therapies for desmoid tumors and neurofibromatosis type 1–related plexiform neurofibromas. SpringWorks Therapeutics is a US-based provider of targeted therapies for rare tumors and genetically defined cancers, including approved treatments for desmoid tumors and NF1-associated plexiform neurofibromas.

Regional Outlook

North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurofibromatosis Type 1 Market?

The neurofibromatosis type 1 (NF1) market consists of revenues earned by entities by providing services such as medical monitoring, genetic counselling, and specialized care. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis type 1 (NF1) market also includes sales of medical devices, MEK inhibitors, anticonvulsants, and analgesics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurofibromatosis Type 1 Market Report 2026?

The neurofibromatosis type 1 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurofibromatosis type 1 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.